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ABSTRACT
Objective: We examined levels and trends in
cardiovascular risk factors and drug treatment in
myocardial infarction (MI) patients with and without
diabetes.
Design: Cross-sectional analysis of baseline Alpha
Omega Trial data, a randomised controlled trial.
Setting: 32 hospitals in the Netherlands.
Participants: In total, we had 1014 MI patients
with diabetes (74% men) and 3823 without diabetes
(79% men) aged 60–80 years, analysed over the
period 2002–2006.
Results: Between 2002 and 2006, a significantly
decreasing trend in the prevalence of obesity (−5%,
ptrend=0.02) and in systolic blood pressure (BP) levels
(−5 mm Hg, ptrend<0.0001) was demonstrated in non-
diabetic patients, but not in diabetic patients. In 2006,
obesity, mean systolic BP and serum triglyceride levels
were significantly higher, whereas high-density
lipoprotein cholesterol levels were lower in diabetic
patients compared to those without. Prescription of
antihypertensive drug (diabetic vs non-diabetic patients
respectively, 95% vs 93%, p=0.08) and statin
treatment were high (86% and 90%, p=0.11).
Conclusions: A high proportion of MI patients with
and without diabetes was similarly treated with
cardiovascular drugs. In spite of high drug treatment
levels, more adverse risk factors were found in patients
with diabetes.
BACKGROUND
The prevalence of type 2 diabetes mellitus is
rising at an alarming rate.1 Globally, there
were 285 million adults with type 2 diabetes
in 2010 which may increase to 439 million by
2030.2 The adverse microvascular and macro-
vascular consequences of diabetes are well
recognised, as is the accompanying rate of
atherosclerosis that predisposes patients to
coronary heart disease (CHD), including
cardiac arrhythmias and sudden death.3 The
prevalence of type 2 diabetes in Europe is
around 7%,2 and typically about 20% of
ARTICLE SUMMARY
Article focus
▪ We examined levels and trends in cardiovascular
risk factors and drug treatment in myocardial infarc-
tion (MI) patients with and without diabetes: 4837
patients with MI, out of which 1014 had type 2 dia-
betes and 3823 had no diabetes.
Key messages
▪ We demonstrated adverse risk factors and deteri-
orating trends over time in patients with type 2
diabetes and MI compared to those without
diabetes.
▪ Despite high cardiovascular drug treatment levels in
both MI patients with and without diabetes, the
prevalence of obesity, mean systolic BP and serum
triglyceride levels were significantly higher, whereas
HDL-cholesterol levels were lower in diabetic
patients compared to those without.
▪ More aggressive drug treatment in combination
with diet and lifestyle interventions could help to
reach the target levels for blood pressure and
lipid lowering.
Strengths and limitations of this study
▪ We used cross-sectional data of a large number
of MI patients with and without diabetes
recruited in collaboration with cardiologists at 32
hospitals in the Netherlands.
▪ We assessed diabetes status by combining self-
reported physician diagnosis, antidiabetic treat-
ment and casual plasma glucose values.
▪ We collected measurements on risk factors and
medication in a standardised manner across all
32 hospitals.
▪ We included volunteers in a clinical trial who
could be healthier and/or better treated than
other MI patients leading to selection-bias.
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patients with CHD have a history of type 2 diabetes.4–7
The survival time after myocardial infarction (MI),
unstable angina or coronary bypass surgery is lower in
patients with diabetes compared to those without.4–8
Several studies showed that risk factor proﬁles were
more adverse in CHD patients with diabetes compared
to those without diabetes between 1995 and 2006.9–11
How this adverse risk factor proﬁle in these diabetes
patients with CHD has developed since then is not
known. This is important to investigate, since the preva-
lence of diabetes will have increased over time. In the
EUROASPIRE study, the prevalence of diabetes already
increased from 17.4% in 1999 to 28.0% by 2006.12 In
comparison with the on-average 10-year younger
EUROASPIRE CHD patients,12 we observed in MI
patients lower levels of obesity, elevated BP, elevated
cholesterol and diabetes, and lower prescription rates of
antiplatelets and β-blockers in 2006.13 Despite lower
observed levels, there was still room for improvement in
cardiovascular risk management and it is unclear as to
whether MI patients with diabetes need a different man-
agement from those without diabetes.
Randomised controlled trials indicated a need for more
aggressive treatment in diabetes patients, for blood
pressure (BP),14 dyslipidemia15 16 and hyperglycemia17 to
reduce CHD. Therefore, several guidelines recommended
stricter target BP levels <130/80 mmHg for patients with
diabetes.18–20 In the Netherlands, on the contrary, recom-
mendations advise similar target BP values in all patients,
including the elderly and diabetes patients, namely <140
mmHg systolic BP.21 22 In American, European and Dutch
guidelines low-density lipoprotein (LDL) cholesterol levels
are recommended to be below 2.5 or 2.6 mmol/l (approxi-
mately 100 mg/dl).18–22 Some guidelines,18 20 but not
all,21 22 recommend even lower LDL cholesterol target
levels of less than 1.8 mmol/l (70 mg/dl) for very high-risk
patients with diabetes and CHD. Whether these guidelines
have effectively been implemented in current practice is
unknown.
The issue was raised as to whether diabetes should be
treated as a coronary risk equivalent.23 A comprehensive
meta-analysis showed that diabetes should not be treated
as a CHD risk equivalent and recommended individual
risk assessment to be used rather than diabetes status
per se.24 Conﬂicting views on whether cardiovascular
risk management in diabetic patients should be different
from those without diabetes triggered us to evaluate this
in clinical practice especially in secondary prevention
where even less evidence exists. Therefore, we examined
differences between MI patients with and without dia-
betes mellitus in cardiovascular risk factors and drug use
between 2002 and 2006.
METHODS
Study design and population
We used baseline cross-sectional data of the Alpha
Omega Trial (www.alphaomegatrial.com), a multicentre
trial on the effect of n-3 fatty acids and cardiovascular
endpoints.25 26 Details of the trial design and patient
inclusion and exclusion criteria were previously
described.25 26 This study involved 4837 men and
women aged 60–80 years with a documented history of
MI who were recruited from 32 hospitals in the
Netherlands between April 2002 and December 2006.
Written informed consent was obtained from each
subject. The study was conducted in accordance with the
Helsinki Declaration and approved by the central
Medical Ethics Committee South-West Holland and local
medical ethics committees of participating hospitals (see
online supplementary material for participating cardi-
ology centres).
Measurements
Patients were physically examined by trained research
nurses who also collected data on health status, lifestyle
and drug treatment by means of self-administered ques-
tionnaires. Smoking status was deﬁned as current, former
or never. Educational level was assessed in nine categories,
the highest being completed university education.
Diabetes was deﬁned as self-reported physician diagnosis,
antidiabetic medication (including insulin) or by casual
plasma glucose concentrations (≥7 mmol/l (126 mg/dl)
for those fasting and ≥11.1 mmol/l (200 mg/dl) for non-
fasting patients). Self-reported medication of the partici-
pants was coded by a pharmaco-epidemiologist according
to the Anatomical Therapeutic Chemical Classiﬁcation
System (ATC).27 ATC codes were C02, C03, C07, C08 and
C09 for BP-lowering medication, C10 for lipid-modifying
medication, A10 for antidiabetic treatment and B01 for all
antithrombotic medication and B01AC speciﬁcally for anti-
platelet therapy.
Weight and height were measured with the patient
wearing light clothes without shoes, and the body mass
index (BMI) was calculated as weight (kg)/height2 (m2).
Overweight was deﬁned as BMI ≥25.0 and <30 kg/m2
and obesity as BMI ≥30.0 kg/m2. Waist circumference
was measured at the midpoint between the bottom rib
and the top of the hipbone. Central obesity was deﬁned
as a waist circumference of ≥88 cm in women or ≥102 cm
in men.28 Systolic and diastolic BP (1st and 5th Korotkoff
sound, respectively) were measured twice at the left
upper arm after a 10 min seated rest with an automatic
device (Omron HEM-711, Omron Healthcare Europe
B.V., Hoofddorp, The Netherlands) and values were aver-
aged. Casual venous blood samples were taken and blood
lipids and glucose were analysed by standard kits using an
autoanalyzer (Hitachi 912, Roche Diagnostics, Basel,
Switzerland). LDL-cholesterol was calculated according
to the Friedewald formula if serum triglyceride levels
were <4 mmol/l.29
Statistical analysis
Data on risk factors and drug treatment are presented
as mean (SD) for continuous normally distributed data,
median (IQR) for skewed data or percentages for
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categorical data. To estimate signiﬁcant differences in
levels of risk factors between those with and without dia-
betes Student’s t-tests were used for continuous variables
and χ2 tests for dichotomous variables. To estimate
adjusted proportions or mean changes over time in risk
factors and medication general linear models were used
with year, age and gender as covariates. The Tukey
method was used to estimate paired differences in risk
factors and drug treatment between 2006 and 2002.30
The p for trend was calculated with age- and gender-
adjusted linear (for continuous variables) or logistic
(for binary variables) regression models with year as the
independent variable. χ2 tests were used to compare pro-
portions of diabetic and non-diabetic patients below
target levels as recommended in current guidelines21 22
for the main (by drug treatment) modiﬁable risk
factors.
Time trend differences in certain risk factors (obesity,
systolic BP) between diabetic and non-diabetic
patients were evaluated with p values for interaction
(diabetes×year).
For all analyses, two-sided p values<0.05 indicated stat-
istical signiﬁcance. SAS version 9.1 (SAS Institute, Cary,
North Carolina, USA) was used for all statistical analyses.
RESULTS
Patients with diabetes (n=1014, 21%) were on average
69.4 years (74% men) and those without diabetes
(n=3823; 79%) were aged 68.9 years (79% men). As
shown in table 1, in 72% of the diabetes cases the diag-
nosis was based on a combination of self-reported phys-
ician diagnosis, antidiabetic medication and elevated
plasma glucose concentrations (≥7 mmol/l (126 mg/dl)
for those fasting and ≥11.1 mmol/l (200 mg/dl) for
non-fasting patients). Of the remaining patients, 10%
had a self-reported physician diagnosis only, 14% had
elevated plasma glucose values and 3% used antidiabetic
medication only.
Table 2 describes risk factors and medication of
patients with and without diabetes. Diabetes patients
were more often women (26%, compared to 21% in
non-diabetic patients), and had higher BMI (29.2 vs
27.4 kg/m2), waist circumference (105.6 vs 101.0 cm)
and plasma glucose values (8.50 vs 5.61 mmol/l; all
p<0.0001). Serum total, LDL and high-density lipopro-
tein (HDL)-cholesterol levels were signiﬁcantly lower
and serum triglyceride levels were signiﬁcantly higher in
diabetes than non-diabetes patients. BP levels, educa-
tional level, antithrombotic drug use and current
smoking levels were similar in both groups.
Table 1 Definition of diabetes in 1014 diabetic
postmyocardial infarction patients recruited for the Alpha
Omega Trial (total n=4837)
Definition N %
Combination self-reported physician
diagnosis, antidiabetic treatment and plasma
glucose values
728 72
Plasma glucose values only* 147 14
Self-reported physician diagnosis only 99 10
Antidiabetic treatment only 34 3
Both treatment and plasma glucose values 6 1
Total 1014 100
*Diabetes defined by plasma glucose values was based on fasting
values (≥7 mmol/l) in 134 or non-fasting values (≥11.1 mmol/l) in
13 patients.
Table 2 Characteristics of myocardial patients with and without diabetes
N missings Diabetes (n=1014) No diabetes (n=3823) p Value
Age (years) 0 69.4 (5.7) 68.9 (5.5) 0.008
Women % (n) 0 26 (267) 21 (787) <0.0001
High education % (n)* 33 11 (106) 13 (491) 0.05
Antithrombotic drugs % (n) 0 97 (981) 98 (3737) 0.06
Statins % (n) 0 83 (844) 86 (3278) 0.04
Antihypertensive drugs % (n) 0 93 (944) 89 (3396) <0.0001
Time since MI (years) 63 4.5 (3.1) 4.2 (3.2) 0.03
BMI (kg/m2) 9 29.2 (4.5) 27.4 (3.6) <0.0001
Waist circumference (cm) 26 105.6 (11.7) 101.0 (9.9) <0.0001
Plasma glucose (mmol/l) 104 8.50 (3.27) 5.61 (1.02) <0.0001
Serum total cholesterol (mmol/l) 131 4.64 (0.96) 4.75 (0.97) 0.003
HDL-c (mmol/l) 131 1.21 (0.33) 1.30 (0.34) <0.0001
LDL-c (mmol/l) 345 2.44 (0.81) 2.62 (0.84) <0.0001
Serum triglycerides (mmol/l)† 131 1.93 (1.37, 2.72) 1.59 (1.18, 2.20) <0.0001
Systolic BP (mm Hg) 6 142.9 (21.8) 141.3 (21.6) 0.04
Diastolic BP (mm Hg) 6 78.2 (10.9) 80.6 (11.2) <0.0001
Current smoking % (n) 1 17 (169) 17 (643) 0.9
*High education=from bachelor degree onwards.
†Median (interquartile range).
BMI, body mass index; BP, blood pressure; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol.
Values are mean (SD) or percentages (n).
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Trends in medication use between 2002 and 2006
Table 3 shows the prevalence of drug treatment and
trends between 2002 and 2006 for all main medication
groups by diabetes status. Almost three-quarters of the
MI patients with diabetes were treated with antidiabetic
drugs. Between 2002 and 2006, there was a signiﬁcant
increase (+13%) in the use of insulin and the use
of biguanides (included only metformin) (+17%),
whereas the use of sulphonylureas decreased signiﬁ-
cantly (−23%). Antithrombotic medication was used by
almost 100% of the patients and did not change over
time. There was a signiﬁcantly increasing trend in statin
use between 2002 and 2006 in both patients with dia-
betes (+8%) and those without (+17%), and similar
levels (86% vs 90%, p=0.11) were observed in 2006.
There was also a signiﬁcant trend in antihypertensive
medication between 2002 and 2006 in patients with dia-
betes (+6%) and in those without (+12%), with similar
levels (95% vs 93%, p=0.08) in 2006. Of all major drug
classes, β-blockers were mostly used (up to 75%). Strong
increases were observed in β-blockers and angiotensin II
receptor blockers in both diabetic and non-diabetic
patients. The use of ACE inhibitors, calcium channel
blockers and diuretics remained stable or slightly
decreased between 2002 and 2006.
Trends in risk factors between 2002 and 2006
Table 4 shows risk factor levels and trends in risk factor
levels between 2002 and 2006 in diabetic and non-diabetic
patients. A signiﬁcantly decreasing trend between 2002 and
2006 in the prevalence of obesity was found in patients
without diabetes only (−5%, p for trend=0.02), but not in
those with diabetes (+2%, p=0.9) (p interaction=0.11). In
2002, 35% of the diabetic patients was obese compared to
25% of those without diabetes (p=0.045). In 2006, the
prevalence of obesity (BMI≥30 kg/m2) was almost twice
as high in diabetic compared to non-diabetic patients
(37% vs 20%, p<0.0001). Plasma glucose levels increased
between 2002 and 2006 in those without diabetes and
remained unchanged in those with diabetes. In 2006,
plasma glucose levels were 3 mmol/l higher in diabetic
compared to non-diabetic patients (p<0.0001).
Lipid levels improved over time, and similar trends
were seen both in those with and without diabetes. In
2006, average serum total cholesterol levels were similar
in diabetic and non-diabetic patients (4.52 vs
4.44 mmol/l, p=0.2). Lower LDL (2.18 vs 2.35, p=0.001)
and HDL-cholesterol (1.28 vs 1.38, p<0.0001) and
0.3 mmol/l higher serum triglyceride levels (p<0.0001)
were found in diabetic patients compared to non-
diabetic patients.
Table 3 Prevalence of drug treatment between 2002 and 2006 by diabetes status
Diabetes (1014) No diabetes (3823)
2002
(94)
% (n)
2006
(330)
% (n)
Change from
2002–2006
p for
trend
2002
(428)
% (n)
2006
(1154)
% (n)
Change from
2002–2006
p for
trend
Glucose-lowering
therapy
65 (61) 72 (236) 6.4% (−6.0, 18.7) 0.4 – – –
Insulin 14 (13) 27 (89) 13.2% (9.2, 25.4) 0.006 – – –
Biguanides 26 (24) 42 (139) 16.8% (3.2, 30.3) 0.008 – – –
Sulphonamides 52 (49) 30 (99) −22.5% (−35.7, −9.3) <0.0001 – – –
Antithrombotic
drugs
97 (91) 97 (320) 0.3% (–4.6, 5.3) 0.7 97 (416) 98 (1133) 0.9% (−1.1, 2.9) 0.02
Antiplatelets 80 (75) 85 (280) 5.6% (−5.2, 16.4) 0.048 82 (349) 84 (975) 2.6% (−2.3, 7.5) 0.15
All lipid-modifying
drugs
80 (75) 87 (288) 7.8% (−2.2, 17.8) 0.03 72 (309) 90 (1043) 17.7 (13.1, 22.3) <0.0001
Statins 79 (74) 86 (285) 7.9% (−2.4, 18.3) 0.03 71 (307) 90 (1033) 17.3% (12.7, 22.0) <0.0001
Other
lipid-modifying
2 (2) 5 (16) 2.8% (−2.7, 8.3) 0.2 2 (7) 3 (40) 1.8% (−0.3, 3.9) 0.02
Antihypertensive
drugs
89 (84) 95 (315) 6.1% (−1.0, 13.1) 0.007 81 (346) 93 (1070) 12.2% (7.9, 16.4) <0.0001
β-blockers 61 (57) 76 (251) 15.7% (3.2, 28.2) 0.0001 52 (224) 75 (863) 22.5% (16.3, 28.7) <0.0001
ACE inhibitors 50 (47) 46 (153) −3.7% (−17.6, 10.3) 0.9 38 (164) 41 (478) 2.9% (−3.8, 9.6) 0.03
Angiotensin II
receptor blockers
(ARBs)
12 (11) 23 (77) 11.5% (0.3, 22.7) 0.03 9 (37) 16 (188) 7.9% (3.3, 12.5) <0.0001
ACE inhibitors
and ARBs
61 (57) 68 (223) 6.8% (−6.4, 20.0) 0.09 47 (200) 57 (655) 10.1% (3.4, 16.9) <0.0001
Calcium-channel
blockers
19 (18) 22 (73) 2.8% (−9.2, 14.8) 0.8 17 (71) 18 (207) 1.5% (−3.8, 3.8) 0.6
Diuretics 39 (37) 39 (128) −1.6% (−14.6, 11.5) 0.7 28 (118) 23 (260) −3.9 (−9.4, 1.5) 0.3
This table represents age-adjusted and sex-adjusted prevalence rates and changes over time (between 2002 and 2006).
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Between 2002 and 2006, a signiﬁcantly decreasing trend
in average systolic BP levels (−5 mmHg, p for trend
<0.0001) was observed in those without diabetes and a
non-signiﬁcant decrease of 3 mm Hg in those with dia-
betes (p for interaction=0.07). As a result, in 2006 mean
systolic BP was signiﬁcantly higher in diabetes patients
compared to those without (142 vs 138 mmHg, p=0.004).
This difference in systolic BP could not be explained by
antihypertensive drug use (table 3), which was high in
2006 (93% and 95%, respectively) in both groups.
On average, current smoking was more prevalent in
2002 in those with diabetes compared to those without
(28% vs 22%). The decreasing trend in the prevalence
of smokers was two times stronger in diabetic (−13%)
than in non-diabetic patients (−7%). In 2006, the preva-
lence of smokers was similar in the two groups (approxi-
mately 15%).
Comparison with current guidelines
Guidelines for cardiovascular risk management in the
Netherlands advise drug treatment to keep serum total
cholesterol <4.5 mmol/l and/or LDL-cholesterol levels
<2.5 mmol/l and systolic BP levels <140 mm Hg for both
diabetic and non-diabetic patients.21 22 In 2006, 73%
of diabetic patients compared to 67% of non-diabetic
patients (p=0.05) had serum total cholesterol and
LDL-cholesterol concentrations in line with the recom-
mendations. In the same year, 45% of diabetic patients
and 56% of non-diabetic patients (p=0.0005) had sys-
tolic BP levels <140 mm Hg.
DISCUSSION
This study showed that in the Netherlands most MI
patients with and without diabetes were treated with car-
diovascular drugs. Diabetes patients were not more
aggressively treated than patients without diabetes. In
2006, the prevalence of obesity, and average systolic
BP and serum triglyceride levels were higher and
HDL-cholesterol levels were lower in those with diabetes
compared to those without.
Strengths of the present study are the large number of
MI patients recruited from 32 geographically distributed
centres in the Netherlands. Data were collected by trained
research nurses who followed a standard protocol for phys-
ical examination. Data on cardiovascular and diabetes
medication were coded by one pharmaco-epidemiologist
according to the ATC classiﬁcation system.
In the present study, diabetes was deﬁned based on
self-reported physician diagnosis, use of antidiabetes
medication and/or elevated casual glucose levels.
Limitations of our diabetes diagnosis are that no oral
glucose tolerance tests (OGTT) were performed.
However, performance of OGTT in cardiological
routine care is limited, mainly due to its time-consuming
protocol, costs and overall inconvenience.20 In the Euro
Heart Survey an OGTT was only carried out in 56% of
the patients with coronary artery disease but without
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known type 2 diabetes.31 In the Netherlands, fasting
plasma glucose is usually measured by cardiologists. The
prevalence of diabetes (20%) corresponded with other
studies in MI patients which showed rates between 20
and 33%.4 7 32 33 Other limitations of our study are that
our patients were volunteers in a clinical trial who could
be healthier and/or better treated than other MI
patients leading to selection-bias. Generalisability may
also be restricted because university hospitals were
underrepresented and MI patients who were severely ill,
living in nursing homes and patients with cognitive
impairment were excluded from the trial. However, the
comparisons between diabetic and non-diabetic patients
were probably similar compared to other patient popula-
tions. Misclassiﬁcation could have occurred for self-
reported risk factors, such as smoking and medication.
The number of patients in each examination year varied
and was limited, but remained sufﬁciently high to
describe diabetes prevalence rates (18%, 21%, 24%,
19%, 22% in subsequent years from 2002 to 2006), risk
factor levels and trends over time.
Many clinical trials on lipid-lowering,34 BP-lowering14 35 36
and antiplatelet drugs37 showed that the relative risk reduc-
tion in CHD risk resulting from risk factor interventions was
similar in diabetic and non-diabetic patients. However, dia-
betes patients have a higher absolute CHD risk and could
potentially beneﬁt more from treatment than non-diabetic
patients. In our study the proportions of antithrombotic,
lipid-modifying and antihypertensive drug use were high
and did not differ between those with and without diabetes.
Approximately 73% of our MI diabetes patients were
pharmacologically treated to control glucose levels.
Previous studies on high-risk diabetic patients with con-
comitant CHD reported similar percentages treated with
insulin (43%), sulphonylureas (27%) and/or metformin
(18–28%).38 39
We found an increasing trend in insulin and metfor-
min and a decreasing trend in sulphonylureas between
2002 and 2006. This suggests that insulin and metformin
(partly) have replaced sulphonylureas. Adverse effects of
sulphonylureas on CHD risk have been reported in dia-
betic patients,39–43 although this was not conﬁrmed in
more recent studies.44 45 The prescription of metformin
showed an increasing trend in the present study
and may reduce mortality in patients with diabetes and
CHD, as observed in observational studies46 and
trials.47 48 A meta-analysis of ﬁve major randomised trials
showed that intensive glucose control signiﬁcantly
reduced the incidence of non-fatal MI (OR 0.83, 95%
CI 0.75 to 0.93) and total CHD events (OR 0.85, 95% CI
0.77 to 0.93).17 This meta-analysis also showed a beneﬁ-
cial effect on macrovascular disease without increasing
all-cause mortality. The numbers needed to treat to
prevent one CHD event is 69 for all patients achieving
on average a 0.9% reduction in glycated haemoglobin
concentrations during 5 years (starting from mean 7.8%
at baseline). The glucose-lowering regimens used in the
ﬁve trials involved mainly metformin, sulphonylureas,
insulin and glitazones, comparable to our study.17
Several studies reported trends in risk factors and medi-
cation in CHD patients12 49 50 and in CHD patients with
and without diabetes,9–11 which were in line with our
study. In the EUROASPIRE study, similar to our study,
1086 CHD patients with diabetes and 4464 without
diabetes were included.9 Similar to our ﬁndings,
EUROASPIRE showed a high prevalence of adverse
lifestyle-related risk factors in European diabetic and non-
diabetic patients with CHD, with a more adverse proﬁle
in diabetic patients. In their diabetic subpopulation
(2000) in comparison with our diabetic patients (2002),
they had less smokers (17% vs 28%) and more obese
patients (43% vs 35%). However, more adverse lipid pro-
ﬁles (eg, LDL-cholesterol 3.2 vs 2.8 mmol/l) were found
in EUROASPIRE II compared to our study, whereas BP
levels were similar. The main differences in medication
were a higher use of calcium antagonists (32% vs 19%), a
lower use of diuretics (25% vs 39%) and a lower use of
statins (56% vs 79%) in EUROASPIRE. We were not able
to compare our 2006 data to EUROASPIRE, since no
update of EUROASPIRE analyses by diabetes status was
published after 2000.
Our ﬁnding that systolic BP levels were not low enough
in diabetic MI patients, despite high treatment levels with
antihypertensives is consistent with that in EUROASPIRE.
The authors9 suggested the following explanations for the
failure to control BP among diabetic CHD patients: misun-
derstanding or negligence of treatment goals by physi-
cians, suboptimal dosages and/or poor compliance by
patients. These suggestions, however, could not be
explored in our data.
Approximately three-quarters of our patients had target
levels of total cholesterol <4.5 mmol/l and LDL-cholesterol
levels<2.5 mmol/l in line with current Dutch recommenda-
tions.21 22 In all recommendations,18–22 lipid-lowering
therapy advise is focused on LDL-cholesterol and total
cholesterol, whereas HDL-cholesterol and triglycerides are
not even mentioned in some guidelines.22 The joint
European guidelines recognise low HDL-cholesterol
(<1 mmol/l (39 mg/dl) in men and <1.2 mmol/l (46 mg/
dl) in women) and fasting triglycerides >1.7 mmol/l
(151 mg/dl) as markers of increased vascular risk.20
Treatment of hypertriglyceridaemia with ﬁbrates is not yet
mentioned in recommendations21 22 due to lack of beneﬁ-
cial effects on long-term complications. A recent
meta-analysis of six randomised controlled trials in patients
with type 2 diabetes did not report an effect of ﬁbrates on
all-cause or cardiac mortality, stroke, unstable angina or
invasive coronary revasculariaation.51
Systolic BP levels target levels below 140 mm Hg as
recommended in the Netherlands21 22 were found in
2006 in just over half of the non-diabetic patients (56%),
and less than half of the diabetic patients (45%). If
(hypothetically) European or American guidelines were
followed with target systolic BP levels <130/80 mm Hg
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even fewer of the diabetic patients would have been
treated accordingly.
This study showed that diabetic patients had more
obesity, higher levels of systolic BP, higher serum triglycer-
ide levels and lower HDL-cholesterol levels compared to
non-diabetic MI patients. According to current guide-
lines, systolic BP levels were controlled in only half of
patients and total serum cholesterol and LDL-cholesterol
levels were controlled in almost three-quarters of
patients. Diabetic patients were not more aggressively
treated than non-diabetic patients and there is scope for
improvement. More aggressive drug treatment in com-
bination with diet and lifestyle interventions could help
to reach the target levels for BP and lipid lowering.
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